A thousand points of light or just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging

Frederick L Moffat, Seza A. Gulec, Aldo N Serafini, George N Sfakianakis, Raoul Pop, David S. Robinson, Dido Franceschi, Jodeen Boggs, Alan Livingstone

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Radioimmunoscintigraphy (RIS) is coming into its own as an imaging modality in clinical oncology. Early experience with indium-111-labeled intact murine monoclonal antibodies (MoAbs) in colorectal cancer suggested that RIS images hepatic metastases poorly. Moreover, an antimurine immune response was frequently provoked, precluding multiple follow-up RIS studies in individual patients due to reticuloendothelial sequestration of the radioimmunoconjugate before tumor targeting could occur. Recent trials of technetium-99m-labeled antibody fragments and human MoAbs have demonstrated significant improvement in imaging efficacy, and repeated or serial imaging is possible because of the absence of associated immunogenicity. RIS is demonstrably more sensitive than conventional diagnostic modalities (CDM) such as computed tomography (CT) for detection of extrahepatic abdominal and pelvic colorectal carcinoma and is complementary to CDM in imaging liver metastases. In a surgical decision-making analysis comparing CT, RIS (IMMU-4 99mTc-Fab'; CEA-Scan®), and CT plus RIS in patients with recurrent or metastatic colorectal cancer, CT plus RIS improved correct prediction of resectability by 40% and correct prediction of unresectability by 100% compared with CT alone. At the present time, RIS used in combination with CDM contributes an incremental improvement in diagnostic accuracy in colorectal cancer patients with known or suspected recurrent disease. Basic and clinical research currently in progress promises to yield agents and methods that provide rapid high-resolution imaging, high tumor-to-background ratios in all organs at risk for tumor recurrence or metastasis, negligible immunogenicity and toxicity, and a significant further improvement in the accuracy of clinical decision making in oncology patients.

Original languageEnglish
Pages (from-to)322-334
Number of pages13
JournalCancer Investigation
Volume17
Issue number5
StatePublished - Jan 1 1999

Fingerprint

Radioimmunodetection
Colorectal Neoplasms
Light
Antibodies
Tomography
Neoplasm Metastasis
Monoclonal Antibodies
Immunoconjugates
Organs at Risk
Neoplasms
Immunoglobulin Fragments
Indium
Medical Oncology
Decision Support Techniques
Liver
Technetium
Decision Making
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A thousand points of light or just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging. / Moffat, Frederick L; Gulec, Seza A.; Serafini, Aldo N; Sfakianakis, George N; Pop, Raoul; Robinson, David S.; Franceschi, Dido; Boggs, Jodeen; Livingstone, Alan.

In: Cancer Investigation, Vol. 17, No. 5, 01.01.1999, p. 322-334.

Research output: Contribution to journalArticle

Moffat, Frederick L ; Gulec, Seza A. ; Serafini, Aldo N ; Sfakianakis, George N ; Pop, Raoul ; Robinson, David S. ; Franceschi, Dido ; Boggs, Jodeen ; Livingstone, Alan. / A thousand points of light or just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging. In: Cancer Investigation. 1999 ; Vol. 17, No. 5. pp. 322-334.
@article{7d83dbc517c84ddf9a9541fb712cb317,
title = "A thousand points of light or just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging",
abstract = "Radioimmunoscintigraphy (RIS) is coming into its own as an imaging modality in clinical oncology. Early experience with indium-111-labeled intact murine monoclonal antibodies (MoAbs) in colorectal cancer suggested that RIS images hepatic metastases poorly. Moreover, an antimurine immune response was frequently provoked, precluding multiple follow-up RIS studies in individual patients due to reticuloendothelial sequestration of the radioimmunoconjugate before tumor targeting could occur. Recent trials of technetium-99m-labeled antibody fragments and human MoAbs have demonstrated significant improvement in imaging efficacy, and repeated or serial imaging is possible because of the absence of associated immunogenicity. RIS is demonstrably more sensitive than conventional diagnostic modalities (CDM) such as computed tomography (CT) for detection of extrahepatic abdominal and pelvic colorectal carcinoma and is complementary to CDM in imaging liver metastases. In a surgical decision-making analysis comparing CT, RIS (IMMU-4 99mTc-Fab'; CEA-Scan{\circledR}), and CT plus RIS in patients with recurrent or metastatic colorectal cancer, CT plus RIS improved correct prediction of resectability by 40{\%} and correct prediction of unresectability by 100{\%} compared with CT alone. At the present time, RIS used in combination with CDM contributes an incremental improvement in diagnostic accuracy in colorectal cancer patients with known or suspected recurrent disease. Basic and clinical research currently in progress promises to yield agents and methods that provide rapid high-resolution imaging, high tumor-to-background ratios in all organs at risk for tumor recurrence or metastasis, negligible immunogenicity and toxicity, and a significant further improvement in the accuracy of clinical decision making in oncology patients.",
author = "Moffat, {Frederick L} and Gulec, {Seza A.} and Serafini, {Aldo N} and Sfakianakis, {George N} and Raoul Pop and Robinson, {David S.} and Dido Franceschi and Jodeen Boggs and Alan Livingstone",
year = "1999",
month = "1",
day = "1",
language = "English",
volume = "17",
pages = "322--334",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - A thousand points of light or just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging

AU - Moffat, Frederick L

AU - Gulec, Seza A.

AU - Serafini, Aldo N

AU - Sfakianakis, George N

AU - Pop, Raoul

AU - Robinson, David S.

AU - Franceschi, Dido

AU - Boggs, Jodeen

AU - Livingstone, Alan

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Radioimmunoscintigraphy (RIS) is coming into its own as an imaging modality in clinical oncology. Early experience with indium-111-labeled intact murine monoclonal antibodies (MoAbs) in colorectal cancer suggested that RIS images hepatic metastases poorly. Moreover, an antimurine immune response was frequently provoked, precluding multiple follow-up RIS studies in individual patients due to reticuloendothelial sequestration of the radioimmunoconjugate before tumor targeting could occur. Recent trials of technetium-99m-labeled antibody fragments and human MoAbs have demonstrated significant improvement in imaging efficacy, and repeated or serial imaging is possible because of the absence of associated immunogenicity. RIS is demonstrably more sensitive than conventional diagnostic modalities (CDM) such as computed tomography (CT) for detection of extrahepatic abdominal and pelvic colorectal carcinoma and is complementary to CDM in imaging liver metastases. In a surgical decision-making analysis comparing CT, RIS (IMMU-4 99mTc-Fab'; CEA-Scan®), and CT plus RIS in patients with recurrent or metastatic colorectal cancer, CT plus RIS improved correct prediction of resectability by 40% and correct prediction of unresectability by 100% compared with CT alone. At the present time, RIS used in combination with CDM contributes an incremental improvement in diagnostic accuracy in colorectal cancer patients with known or suspected recurrent disease. Basic and clinical research currently in progress promises to yield agents and methods that provide rapid high-resolution imaging, high tumor-to-background ratios in all organs at risk for tumor recurrence or metastasis, negligible immunogenicity and toxicity, and a significant further improvement in the accuracy of clinical decision making in oncology patients.

AB - Radioimmunoscintigraphy (RIS) is coming into its own as an imaging modality in clinical oncology. Early experience with indium-111-labeled intact murine monoclonal antibodies (MoAbs) in colorectal cancer suggested that RIS images hepatic metastases poorly. Moreover, an antimurine immune response was frequently provoked, precluding multiple follow-up RIS studies in individual patients due to reticuloendothelial sequestration of the radioimmunoconjugate before tumor targeting could occur. Recent trials of technetium-99m-labeled antibody fragments and human MoAbs have demonstrated significant improvement in imaging efficacy, and repeated or serial imaging is possible because of the absence of associated immunogenicity. RIS is demonstrably more sensitive than conventional diagnostic modalities (CDM) such as computed tomography (CT) for detection of extrahepatic abdominal and pelvic colorectal carcinoma and is complementary to CDM in imaging liver metastases. In a surgical decision-making analysis comparing CT, RIS (IMMU-4 99mTc-Fab'; CEA-Scan®), and CT plus RIS in patients with recurrent or metastatic colorectal cancer, CT plus RIS improved correct prediction of resectability by 40% and correct prediction of unresectability by 100% compared with CT alone. At the present time, RIS used in combination with CDM contributes an incremental improvement in diagnostic accuracy in colorectal cancer patients with known or suspected recurrent disease. Basic and clinical research currently in progress promises to yield agents and methods that provide rapid high-resolution imaging, high tumor-to-background ratios in all organs at risk for tumor recurrence or metastasis, negligible immunogenicity and toxicity, and a significant further improvement in the accuracy of clinical decision making in oncology patients.

UR - http://www.scopus.com/inward/record.url?scp=0344142493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344142493&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 322

EP - 334

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 5

ER -